Thursday 16 October, 2025
Introduction: Nosocomial urinary tract infections (UTIs) caused by Gram-positive bacteria, mainly Staphylococcus and Enterococcus species, pose significant clinical challenges[1,2]. Many…
Read morePoster: Clinical Applications
Population pharmacokinetics of total and unbound concentrations of intravenous caspofungin in Chinese critically ill pediatric patients
Thursday 16 October, 2025
Introduction Caspofungin is currently the first-line treatment for invasive fungal infections (IFIs) in the pediatric intensive care unit (PICU) population…
Read moreDynamic interaction modeling of adalimumab and anti-drug antibodies in ankylosing spondylitis
Thursday 16 October, 2025
Objective: Adalimumab (ADAL), a human immunoglobulin G1 monoclonal antibody, has been approved for the treatment of ankylosing spondylitis, a disease…
Read moreModel-based meta-analysis of targeted therapies in systemic lupus erythematosus and its manifestations
Thursday 16 October, 2025
Introduction: The development of targeted therapies for autoimmune diseases has enhanced treatment efficacy while reducing the need for general immunosuppressive…
Read moreAdvancing 5-FU precision dosing: external PK model evaluation, generic PK model development, novel limited sampling strategies and fit-for-use shiny application
Thursday 16 October, 2025
Objectives: 5-Fluorouracil (5-FU) is the cornerstone of first-line chemotherapy for various gastrointestinal cancers[1]. However, up to 76% of the patients…
Read morePopulation PK/PD Modeling to Predict Efficacy of Extended Dosing of Amlitelimab in Moderate-to-Severe Atopic Dermatitis Patients
Thursday 16 October, 2025
Introduction & Objectives: Amlitelimab is a fully human, non-depleting, anti-OX40L monoclonal antibody that binds to OX40L on antigen-presenting cells (APCs),…
Read moreEvaluation of population pharmacokinetic model predictive performance in adults on hemodialysis treated with vancomycin
Thursday 16 October, 2025
Introduction: The pharmacokinetics (PK) of vancomycin in patients undergoing hemodialysis is significantly influenced by both the hemodialysis process itself and…
Read moreLinking Abemaciclib Exposure and Early Toxicity in HR+/HER2- Breast Cancer Patients: Insights from Real-World Data
Thursday 16 October, 2025
Objectives Abemaciclib, an oral cyclin-dependent kinase 4/6 inhibitor, is approved for the treatment of HR+/HER2- advanced breast cancer and as…
Read moreModel-Based Approach for a New Prolonged-Release (PR) Formulation of Ivabradine: PK and PKPD Assessment to Support Bioequivalence
Thursday 16 October, 2025
Introduction: Ivabradine is a specific HR-reducing agent, named If inhibitors, that was developed for the treatment of chronic heart failure…
Read morePhysiologically based pharmacokinetic modelling to predict antibody exposure in patients with hepatic impairment
Thursday 16 October, 2025
Introduction Hepatic impairment (HI) is a common comorbidity in cancer patients [1]. Monoclonal antibodies (mAbs) are frequently used in cancer…
Read more